Where We operate
- Asia-Pacific
- North America
Australia
- High quality research, facilities and equipment
- Fast set-up and approval times
- Sponsor can claim R&D cash refund
Greater China
- Very large, homogenous population
- Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
- Largest clinical trial hub in Asia, with over 17,000 active investigators
India
- Large treatment-naïve population
- High disease population load
- The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
- About 1,800 investigators have participated on a minimum of 5 studies
Malaysia
- Multiethnic Asian population
- Streamlined regulatory system and Strong govt. support
- Quick start-up timelines
- Low patient costs and IRB fees
Philippines
- Large treatment-naïve population
- Low costs
- Overall good level of English
Singapore
- Multiethnic Asian population
- Regional clinical research hub
- Efficient regulatory process and good infrastructure
South Korea
- Homogenous and concentrated population
- High quality medical services and excellent infrastructure
- The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018
Thailand
- Large homogenous population
- High prevalence of communicable diseases
- Efficient regulatory system
- Low operational cost
United States of America
As part of a service expansion program, Novotech has acquired US CRO NCGS, a full service CRO managing clinical trials since 1984 and can now offer CRO services to biotech clients in the US to support early and late phase global studies.
New Zealand
- High-quality research, facilities and equipment
- Fast set-up and approval times
- Sponsor can claim R&D cash refund